iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 1647

Identifiers

  • Canonical SMILES: 
    Cc1noc(C)c1-c1ccc(OCCCN2CCOCC2)c(c1)S(=O)(=O)NC1CCCC1
  • IUPAC name: 
    N-cyclopentyl-5-(dimethyl-1,2-oxazol-4-yl)-2-[3-(morpholin-4-yl)propoxy]benzenesulfonamide
  • InChi: 
    InChI=1S/C23H33N3O5S/c1-17-23(18(2)31-24-17)19-8-9-21(30-13-5-10-26-11-14-29-15-12-26)22(16-19)32(27,28)25-20-6-3-4-7-20/h8-9,16,20,25H,3-7,10-15H2,1-2H3
  • InChiKey: 
    AXHJWOJNGFRTGJ-UHFFFAOYSA-N

External links


56924692
CHEMBL2181718

External search

Bibliography (1)

Publication Name
Bamborough P, Diallo H, Goodacre JD, Gordon L, Lewis A, Seal JT, Wilson DM, Woodrow MD, Chung CW. . Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. Journal of medicinal chemistry. 34

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
8 1 0 0

Targets

PPI family Best activity Diseases MMoA
Bromodomain / Histone 6.00 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 463.21 g/mol
HBA 8
HBD 1
HBA + HBD 9
AlogP 2.20
TPSA 93.90
RB 8
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 8 1 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
22136469 34 BRD2
P25440
Biochemical assay Time-Resolved FRET pIC50 (half maximal inhibitory concentration, -log10) 5.80
22136469 34 BRD3
Q15059
Biochemical assay Time-Resolved FRET pIC50 (half maximal inhibitory concentration, -log10) 5.90
22136469 34 BRD4
O60885
Biochemical assay Time-Resolved FRET pIC50 (half maximal inhibitory concentration, -log10) 5.60
22136469 34 BRD2
P25440
Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 5.50
22136469 34 BRD3
Q15059
Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 6.00
22136469 34 BRD4
O60885
Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 5.50
22136469 34 BRD4
O60885
Cellular assay LPS-stimulated IL6 production PBMC pIC50 (half maximal inhibitory concentration, -log10) 5.50
22136469 34 BRD2
P25440
Biochemical assay Surface Plasmon Resonance pKd (dissociation constant, -log10) 5.50
22136469 34 BRD4
O60885
Biochemical assay Surface Plasmon Resonance pKd (dissociation constant, -log10) 5.56
Ta Structure Name Drugbank ID
0.5784 Parecoxib DB08439
0.4944 Valdecoxib DB00580
0.4070 N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE DB07527
0.4056 AUY922 DB11881
0.3983 Repinotan DB06506
0.3976 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide DB06961
0.3933 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE DB08213
0.3911 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE DB06964
0.3911 N-[2-Hydroxy-2-(8-Isopropyl-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-11-Yl)-Ethyl]-N-(3-Methyl-Butyl)-Benzenesulfonamide,Inhibitor 3 DB03768
0.3872 Glisoxepide DB01289
0.3814 Tamsulosin DB00706
0.3799 Acetyl sulfisoxazole DB14033
0.3761 2-(11-{2-[Benzenesulfonyl-(3-Methyl-Butyl)-Amino]-1-Hydroxy-Ethyl}-6,9-Dioxo-2-Oxa-7,10-Diaza-Bicyclo[11.2.2]Heptadeca-1(16),13(17),14-Trien-8-Yl)-Acetamide, Inhibitor 2 DB02411
0.3726 N-({6-[(4-CYANO-2-FLUOROBENZYL)OXY]NAPHTHALEN-2-YL}SULFONYL)-D-GLUTAMIC ACID DB08112
0.3692 Satavaptan DB14923